FDA Experts Back New ‘Morning-After’ Pill

A panel of experts has endorsed approval of a new “morning-after pill” that works longer than the ones now on the market. The panel voted June 17 to recommend approval of ellaOne, made by HRA Pharma. Canadian Press wrote about the vote. The U.S. Food and Drug Administration is not required to follow its expert panels’ advice. However, it often does. Studies done by the drug maker showed that ellaOne prevents pregnancy when taken up to 5 days after unprotected sex. Plan B, an older brand, can be taken up to 3 days after sex. It is made by Teva Pharmaceuticals. Generic versions also are sold. In a study, 1,700 women received either ellaOne or Plan B between 3 and 5 days after sex. The risk of becoming pregnant was 1.8% of women who took ellaOne. It was 2.6% for those who took Plan B. Abortion opponents have criticized the makers of ellaOne.

Content restricted. Requires subscription

Report Explores Cancer, Diabetes Links

Both diabetes and high insulin levels may increase the risk of some cancers, experts say. This finding is part of a new report. It was sponsored by the American Cancer Society and the American Diabetes. The two groups recruited a panel of experts who looked at previous research. The panel found that people with diabetes have an increased risk of liver, pancreas, endometrial, colon/rectal, breast and bladder cancers. Prostate cancer risk may be below average. The reasons for all of these links are unclear. But there are potential reasons that would make biological sense, the lead author told HealthDay News. For example, insulin and similar proteins in the body can promote some cancers. Many people with type 2 diabetes have high levels of insulin in their bodies. Obesity and some other factors also increase the risk for both diabetes and cancer.

Content restricted. Requires subscription